KalVista Pharmaceuticals, Inc. (KALV) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Arbutus Biopharma Corp.

Liquidia Corp.

Coherus BioSciences, Inc.

Marinus Pharmaceuticals, Inc.

SIGA Technologies, Inc.

Nurix Therapeutics, Inc.

ARS Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc.

Cullinan Therapeutics, Inc.

Icosavax, Inc.

Why is KalVista Pharmaceuticals, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is KalVista Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

KalVista Pharmaceuticals, Inc.

106.26%

1.74

71.60%

S&P 500

25.22%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

81.40%

EBIT Growth (5y)

-208.64%

EBIT to Interest (avg)

-87.67

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.18

Sales to Capital Employed (avg)

0.11

Tax Ratio

1.88%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-365.23

EV to EBIT

-5.61

EV to EBITDA

-5.65

EV to Capital Employed

-32.72

EV to Sales

12.84

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company

NET SALES(HY)

At USD 100.79 MM has Grown at 6,967.88%

RAW MATERIAL COST(Y)

Fallen by -126.71% (YoY

CASH AND EQV(HY)

Highest at USD 585.24 MM

PRE-TAX PROFIT(Q)

At USD -23.49 MM has Grown at 59.46%

NET PROFIT(Q)

At USD -23.49 MM has Grown at 60.92%

-9What is not working for the Company

INTEREST(HY)

At USD 14.23 MM has Grown at 120.16%

DEBT-EQUITY RATIO (HY)

Highest at 3.65 %

Here's what is working for KalVista Pharmaceuticals, Inc.

Net Sales

At USD 100.79 MM has Grown at 6,967.88%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Pre-Tax Profit

At USD -23.49 MM has Grown at 59.46%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD -23.49 MM has Grown at 60.92%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Cash and Eqv

Highest at USD 585.24 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -126.71% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for KalVista Pharmaceuticals, Inc.

Interest

At USD 14.23 MM has Grown at 120.16%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Debt-Equity Ratio

Highest at 3.65 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio